661 related articles for article (PubMed ID: 29897841)
1. Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy.
Sridhar S; Luedtke A; Langevin E; Zhu M; Bonaparte M; Machabert T; Savarino S; Zambrano B; Moureau A; Khromava A; Moodie Z; Westling T; Mascareñas C; Frago C; Cortés M; Chansinghakul D; Noriega F; Bouckenooghe A; Chen J; Ng SP; Gilbert PB; Gurunathan S; DiazGranados CA
N Engl J Med; 2018 Jul; 379(4):327-340. PubMed ID: 29897841
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America.
Forrat R; Dayan GH; DiazGranados CA; Bonaparte M; Laot T; Capeding MR; Sanchez L; Coronel DL; Reynales H; Chansinghakul D; Hadinegoro SRS; Perroud AP; Frago C; Zambrano B; Machabert T; Wu Y; Luedtke A; Price B; Vigne C; Haney O; Savarino SJ; Bouckenooghe A; Noriega F
Clin Infect Dis; 2021 Sep; 73(6):1003-1012. PubMed ID: 33822015
[TBL] [Abstract][Full Text] [Related]
3. Efficacy after 1 and 2 doses of CYD-TDV in dengue endemic areas by dengue serostatus.
Dayan GH; Langevin E; Forrat R; Zambrano B; Noriega F; Frago C; Bouckenooghe A; Machabert T; Savarino S; DiazGranados CA
Vaccine; 2020 Sep; 38(41):6472-6477. PubMed ID: 32773243
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of a tetravalent dengue vaccine in children in Latin America.
Villar L; Dayan GH; Arredondo-García JL; Rivera DM; Cunha R; Deseda C; Reynales H; Costa MS; Morales-Ramírez JO; Carrasquilla G; Rey LC; Dietze R; Luz K; Rivas E; Miranda Montoya MC; Cortés Supelano M; Zambrano B; Langevin E; Boaz M; Tornieporth N; Saville M; Noriega F;
N Engl J Med; 2015 Jan; 372(2):113-23. PubMed ID: 25365753
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the long-term efficacy of a dengue vaccine against symptomatic, virologically-confirmed dengue disease by baseline dengue serostatus.
Dayan GH; Langevin E; Gilbert PB; Wu Y; Moodie Z; Forrat R; Price B; Frago C; Bouckenooghe A; Cortes M; Noriega F; DiazGranados CA
Vaccine; 2020 Apr; 38(19):3531-3536. PubMed ID: 32204943
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study.
Coronel-MartÍnez DL; Park J; López-Medina E; Capeding MR; Cadena Bonfanti AA; Montalbán MC; Ramírez I; Gonzales MLA; DiazGranados CA; Zambrano B; Dayan G; Savarino S; Chen Z; Wang H; Sun S; Bonaparte M; Rojas A; Ramírez JC; Verdan MA; Noriega F
Lancet Infect Dis; 2021 Apr; 21(4):517-528. PubMed ID: 33212067
[TBL] [Abstract][Full Text] [Related]
7. Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with five commercially available immunoassays: a retrospective analysis of phase 3 efficacy trials.
DiazGranados CA; Bonaparte M; Wang H; Zhu M; Lustig Y; Schwartz E; Forrat R; Dayan GH; Hodge S; Ataman-Önal Y; Savarino SJ
Lancet Infect Dis; 2021 Apr; 21(4):529-536. PubMed ID: 33212068
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease.
Hadinegoro SR; Arredondo-García JL; Capeding MR; Deseda C; Chotpitayasunondh T; Dietze R; Muhammad Ismail HI; Reynales H; Limkittikul K; Rivera-Medina DM; Tran HN; Bouckenooghe A; Chansinghakul D; Cortés M; Fanouillere K; Forrat R; Frago C; Gailhardou S; Jackson N; Noriega F; Plennevaux E; Wartel TA; Zambrano B; Saville M;
N Engl J Med; 2015 Sep; 373(13):1195-206. PubMed ID: 26214039
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial.
Biswal S; Borja-Tabora C; Martinez Vargas L; Velásquez H; Theresa Alera M; Sierra V; Johana Rodriguez-Arenales E; Yu D; Wickramasinghe VP; Duarte Moreira E; Fernando AD; Gunasekera D; Kosalaraksa P; Espinoza F; López-Medina E; Bravo L; Tuboi S; Hutagalung Y; Garbes P; Escudero I; Rauscher M; Bizjajeva S; LeFevre I; Borkowski A; Saez-Llorens X; Wallace D;
Lancet; 2020 May; 395(10234):1423-1433. PubMed ID: 32197105
[TBL] [Abstract][Full Text] [Related]
10. Secondary Analysis of the Efficacy and Safety Trial Data of the Tetravalent Dengue Vaccine in Children and Adolescents in Colombia.
Reynales H; Carrasquilla G; Zambrano B; Cortés S M; Machabert T; Jing J; Pallardy S; Haney O; Faccini M; Quintero J; Noriega F
Pediatr Infect Dis J; 2020 Apr; 39(4):e30-e36. PubMed ID: 32040014
[TBL] [Abstract][Full Text] [Related]
11. Development of an anti-dengue NS1 IgG ELISA to evaluate exposure to dengue virus.
Nascimento EJM; George JK; Velasco M; Bonaparte MI; Zheng L; DiazGranados CA; Marques ETA; Huleatt JW
J Virol Methods; 2018 Jul; 257():48-57. PubMed ID: 29567514
[TBL] [Abstract][Full Text] [Related]
12. Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials.
Gailhardou S; Skipetrova A; Dayan GH; Jezorwski J; Saville M; Van der Vliet D; Wartel TA
PLoS Negl Trop Dis; 2016 Jul; 10(7):e0004821. PubMed ID: 27414655
[TBL] [Abstract][Full Text] [Related]
13. Impact of Dengue Vaccination on Serological Diagnosis: Insights From Phase III Dengue Vaccine Efficacy Trials.
Plennevaux E; Moureau A; Arredondo-García JL; Villar L; Pitisuttithum P; Tran NH; Bonaparte M; Chansinghakul D; Coronel DL; L'Azou M; Ochiai RL; Toh ML; Noriega F; Bouckenooghe A
Clin Infect Dis; 2018 Apr; 66(8):1164-1172. PubMed ID: 29300876
[TBL] [Abstract][Full Text] [Related]
14. Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with a new dengue rapid diagnostic test: a retrospective analysis of phase 3 efficacy trials.
Savarino SJ; Bonaparte M; Wang H; Dayan GH; Forrat R; Zhu M; Hodge S; Ataman-Önal Y; DiazGranados CA
Lancet Microbe; 2022 Jun; 3(6):e427-e434. PubMed ID: 35659904
[TBL] [Abstract][Full Text] [Related]
15. Analysis of Neutralizing Antibodies as a Correlate of Instantaneous Risk of Hospitalized Dengue in Placebo Recipients of Dengue Vaccine Efficacy Trials.
Huang Y; Williamson BD; Moodie Z; Carpp LN; Chambonneau L; DiazGranados CA; Gilbert PB
J Infect Dis; 2022 Jan; 225(2):332-340. PubMed ID: 34174082
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial.
Dubey AP; Agarkhedkar S; Chhatwal J; Narayan A; Ganguly S; Wartel TA; Bouckenooghe A; Menezes J
Hum Vaccin Immunother; 2016; 12(2):512-8. PubMed ID: 26291554
[TBL] [Abstract][Full Text] [Related]
17. Symptomatic Dengue in Children in 10 Asian and Latin American Countries.
L'Azou M; Moureau A; Sarti E; Nealon J; Zambrano B; Wartel TA; Villar L; Capeding MR; Ochiai RL; ;
N Engl J Med; 2016 Mar; 374(12):1155-66. PubMed ID: 27007959
[TBL] [Abstract][Full Text] [Related]
18. Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America.
Arredondo-García JL; Hadinegoro SR; Reynales H; Chua MN; Rivera Medina DM; Chotpitayasunondh T; Tran NH; Deseda CC; Wirawan DN; Cortés Supelano M; Frago C; Langevin E; Coronel D; Laot T; Perroud AP; Sanchez L; Bonaparte M; Limkittikul K; Chansinghakul D; Gailhardou S; Noriega F; Wartel TA; Bouckenooghe A; Zambrano B;
Clin Microbiol Infect; 2018 Jul; 24(7):755-763. PubMed ID: 29408333
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America.
Moodie Z; Juraska M; Huang Y; Zhuang Y; Fong Y; Carpp LN; Self SG; Chambonneau L; Small R; Jackson N; Noriega F; Gilbert PB
J Infect Dis; 2018 Feb; 217(5):742-753. PubMed ID: 29194547
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study.
Sáez-Llorens X; Tricou V; Yu D; Rivera L; Jimeno J; Villarreal AC; Dato E; Mazara S; Vargas M; Brose M; Rauscher M; Tuboi S; Borkowski A; Wallace D
Lancet Infect Dis; 2018 Feb; 18(2):162-170. PubMed ID: 29122463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
